Company Description

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.

It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

AEON Biopharma, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Robert Bancroft

Contact Details

Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States
Phone	949 354 6499
Website	aeonbiopharma.com

Stock Details

Ticker Symbol	AEON
Exchange	NYSEAMERICAN
Stock Type	Common Stock
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1837607
CUSIP Number	00791X209
ISIN Number	US00791X2099
Employer ID	85-3940478
SIC Code	2834

Key Executives

Name	Position
Robert Bancroft	President, Chief Executive Officer and Director
Alex Wilson	Chief Legal and Strategy Officer and Corporate Secretary
Dr. Chad K. Oh M.D.	Chief Medical Officer
John A. Bencich M.B.A.	Chief Financial Officer

Latest SEC Filings

Date	Type	Title
Jul 21, 2026	SCHEDULE 13G	Filing
Jul 15, 2026	8-K	Current Report
Jul 15, 2026	424B4	Prospectus
Jul 13, 2026	EFFECT	Notice of Effectiveness
Jul 13, 2026	S-1MEF	Registration adding securities to prior Form S-1 registration
Jul 9, 2026	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
Jul 8, 2026	S-1	General form for registration of securities under the Securities Act of 1933
Jun 17, 2026	8-K	Current Report
May 29, 2026	DRS	[Cover] Draft Registration Statement
May 14, 2026	8-K	Current Report

View All SEC Filings